BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

Related Keywords

California ,United States ,Stanford School ,Massachusetts ,Ukraine ,American ,John Mullaly ,Kim Thacker ,Netta Blondheim Shraga ,Chaim Lebovits ,Antal Pearl Lendner ,Jonathan Katz ,Ralph Kern ,Sidney Spector ,Lisa Guiterman ,James Berry ,Drug Administration For Nurown ,Stanford School Of Medicine ,California Pacific Medical Center ,Research Development ,Preclinical Research ,Nasdaq ,International Society For Extracellular Vesicles ,Neurology Department ,California Institute For Regenerative Medicine ,Brainstorm Cell Therapeutics Inc ,European Network For The Cure ,Lifesci Advisors ,Drug Administration ,International Society ,Drug Development Summit ,Prnewswire Brainstorm Cell Therapeutics Inc ,Consortium Of Multiple Sclerosis Centers ,National Ms Society ,European Medicines Agency ,American Academy Of Neurology Congress ,Biologics License Application ,Storm Cell Therapeutics ,Cell Therapeutics ,Chief Executive ,Second Quarter ,Forbes Norris ,California Pacific Medical ,Neurology Congress ,Massachusetts General Hospital Multidisciplinary ,Motor Neuron ,Development Summit ,Chief Medical Officer ,Comprehensive Longitudinal Investigation ,Multiple Sclerosis ,Multiple Sclerosis Centers ,Christopher Lock ,Clinical Associate Professor ,Neurological Studies ,Senior Vice President ,Medical Affairs ,Global Strategy ,Brainstorm Cell ,Extracellular Vesicles ,Haggai Kaspi ,Preclinical Research Manager ,Gene Therapy ,Clinical Innovation ,Chief Legal ,Second Quarter Ended June ,Access Code ,Orphan Drug ,California Institute ,Regenerative Medicine ,Brainstorm Cell Therapeutics ,Sci Advisors ,Term Assets ,Term Liabilities ,